These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 641542)

  • 1. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.
    Fuller RW; Perry KW
    J Neural Transm; 1978; 42(1):23-35. PubMed ID: 641542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms.
    Beart PM; Gundlach AL
    Br J Pharmacol; 1980 Jun; 69(2):241-7. PubMed ID: 6108139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of the formation rate of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in various rat brain areas.
    Westerink BH; Spaan SJ
    Brain Res; 1982 Dec; 252(2):239-45. PubMed ID: 7150951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of amantadine and amfonelic acid on dopamine metabolism in rat brain.
    Fuller RW; Snoddy HD; Perry KW
    Brain Res Bull; 1981 Feb; 6(2):141-3. PubMed ID: 7470959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.
    Roth RH; Murrin LC; Walters JR
    Eur J Pharmacol; 1976 Mar; 36(1):163-71. PubMed ID: 177297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro.
    Kebabian JW; Calne DB; Kebabian PR
    Commun Psychopharmacol; 1977; 1(4):311-8. PubMed ID: 615694
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine, noradrenaline and 3,4-dihydroxyphenylacetic acid (DOPAC) levels of individual brain nuclei, effects of haloperidol and pargyline.
    Fekete MI; Herman JP; Kanyicska B; Palkovits M
    J Neural Transm; 1979; 45(3):207-18. PubMed ID: 479873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased transport of 3,4-dihydroxyphenylacetic acid from brain during performance of operant behavior in the rat.
    Heffner TG; Vosmer G; Seiden LS
    Brain Res; 1984 Feb; 293(1):85-91. PubMed ID: 6200185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced metabolism and turnover rates of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimelidine treatments.
    Karoum F; Korpi ER; Linnoila M; Chuang LW; Wyatt RJ
    Eur J Pharmacol; 1984 Apr; 100(2):137-44. PubMed ID: 6234178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine.
    Mignot E; Laude D
    J Neurochem; 1985 Nov; 45(5):1527-33. PubMed ID: 2864397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain.
    Jiang DH; Reches A; Wagner HR; Fahn S
    Neuropharmacology; 1984 Mar; 23(3):295-301. PubMed ID: 6539428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the origin of rat hippocampal dihydroxyphenylacetic acid using microdialysis.
    Vahabzadeh A; Fillenz M
    Neurosci Lett; 1992 Feb; 136(1):51-5. PubMed ID: 1353258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
    Steranka LR
    Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of sulfpride and ergot derivatives on rat brain DOPAC concentration and prolactin secretion in vivo.
    Hofmann M; Battaini F; Tonon G; Trabucchi M; Spano P
    Eur J Pharmacol; 1979 Jun; 56(1-2):15-20. PubMed ID: 467503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
    Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice.
    Saitoh T; Mizuno Y; Nagatsu T; Yoshida M
    Neurosci Lett; 1988 Oct; 92(3):321-4. PubMed ID: 3200488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of centrally administered neuropeptide Y (NPY) and NPY13-36 on the brain monoaminergic systems of the rat.
    Heilig M; Vècséi L; Wahlestedt C; Alling C; Widerlöv E
    J Neural Transm Gen Sect; 1990; 79(3):193-208. PubMed ID: 2297403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine neurons: effect of lergotrile on unit activity and transmitter synthesis.
    Walters JR; Lakoski JM; Baring MD; Eng N
    Eur J Pharmacol; 1979 Dec; 60(2-3):199-210. PubMed ID: 43259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.